Comparative Pharmacology
Head-to-head clinical analysis: VEKLURY versus XERESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEKLURY versus XERESE.
VEKLURY vs XERESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Remdesivir is a nucleotide analog prodrug that, after intracellular metabolism, incorporates into nascent viral RNA chains causing synthesis termination and inhibition of RNA-dependent RNA polymerase (RdRp). It targets the SARS-CoV-2 RdRp with selectivity over human RNA polymerases.
XERESE is a fixed-dose combination of clobetasol propionate (a corticosteroid) and acitretin (a retinoid). Clobetasol propionate binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines and reduce inflammation. Acitretin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating keratinocyte proliferation and differentiation.
200 mg IV on Day 1, then 100 mg IV once daily for 5 to 10 days.
One vaginal tablet (100 mg clindamycin + 200 mg clotrimazole) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Remdesivir: ~1 hour (parent); GS-441524: ~27 hours (terminal). Context: GS-441524 accumulation may occur with daily dosing.
Terminal half-life is approximately 8.5 hours (6–11 h) in healthy adults, supporting twice-daily dosing.
Renal: 10% unchanged remdesivir; 49% as metabolite GS-441524; 18% as other metabolites. Fecal: 47.5% as metabolites. Biliary: minor.
Renal: ~51% as unchanged drug; fecal: ~33% (partially as metabolites).
Category C
Category C
Antiviral
Antiviral